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Abstract:  The use of wearable motion sensing technology offers important advantages 
over conventional methods for obtaining measures of physical activity and/or physical 
functioning in individuals with chronic diseases. This review aims to identify the actual 
state of applying wearable systems for monitoring mobility-related activity in individuals 
with chronic disease conditions. In this review we focus on technologies and applications, 
feasibility and adherence aspects, and clinical relevance of wearable motion sensing 
technology. PubMed (Medline since 1990), PEdro, and reference lists of all relevant 
articles were searched. Two authors independently reviewed randomised trials 
systematically. The quality of selected articles was scored and study results were 
summarised and discussed. 163 abstracts were considered. After application of inclusion 
criteria and full text reading, 25 articles were taken into account in a full text review. 
Twelve of these papers evaluated walking with pedometers, seven used uniaxial 
accelerometers to assess physical activity, six used multiaxial accelerometers, and two 
papers used a combination approach of a pedometer and a multiaxial accelerometer for 
obtaining overall activity and energy expenditure measures. Seven studies mentioned 
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feasibility and/or adherence aspects. The number of studies that use movement sensors for 
monitoring of activity patterns in chronic disease (postural transitions, time spent in certain 
positions or activities) is nonexistent on the RCT level of study design. Although feasible 
methods for monitoring human mobility are available, evidence-based clinical applications 
of these methods in individuals with chronic diseases are in need of further development. 
Keywords: biosensors; movement analysis; mobility; locomotion; rehabilitation; healthcare 
 
1. Introduction 
Chronic diseases are leading causes of death and disability in both developed and developing 
countries [1,2]. Chronic disease conditions and diseases that directly influence the components of 
fitness and performance are related to perceived health among middle-aged and older adults [3-5]. 
Inactivity is at the origin of several chronic diseases [6], and regular physical activity substantially 
modifies the development and progression of most chronic degenerative disease states [7]. Thus, it is 
not surprising that exercise is considered to play a critical role in the management of chronic   
illnesses [8,9]. Avoidance of a sedentary lifestyle by engaging in at least some daily physical activity is 
a prudent recommendation for reducing the risk of developing chronic diseases and postponing 
premature mortality at any age [7]. 
Because functional status is an important factor affecting quality of life and healthcare   
utilization [10], valid outcome measures of physical activity and/or physical functioning are of utmost 
importance. Especially an understanding of the quantity and quality of physical (in)activity is 
particularly important in addressing rehabilitation needs of the individual with a chronic disease. 
Several tools are available for measuring physical activity (PA). PA can be measured by the use of 
questionnaires, interviews or a diary. However, these methods are mostly retrospective and contain a 
subjective judgement which leads to a certain amount of imprecision causing limited reliability [11]. 
Objective, performance-based measures of physical function have the disadvantage that performance 
at the time of assessment may not represent the usual performance of the tested individual [12]. The 
alternative to assess outcomes through proxy is only recommended for individuals who cannot be 
evaluated with other methods. This method also seems to have limited reliability and validity [13] and 
seems unsuitable for longer time periods of measurement [14]. 
A recent development is the use of wearable motion sensing technology for studying human 
movement. Based on the use of miniaturised motion sensors, methods are available for long-term 
monitoring of daily PA and the assessment of motor functioning under real-life conditions [15]. These 
methods are relevant for studying motor functioning in older people [11], but as yet it is unclear to 
what extent and with what effect such methods have been applied in individuals with chronic disease 
conditions. The variety of studies, providing a wealth of experimental data, makes it difficult to get a 
clear view of the clinical relevance of these methods for the assessment of physical functioning. An 
overview of application methods in patients suffering from chronic diseases is currently lacking. 
In the present study, we review and evaluate the application of wearable motion sensing technology 
for monitoring mobility-related activity in individuals with chronic diseases. We used the International Sensors 2010, 10                                       
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Classification of Functioning, Disability, and Health (ICF) as a reference to organize the results and to 
limit the scope of this study [16]. Mobility in this context is changing and maintaining body position 
(ICF d410-d429) or walking and moving (ICF d450-d469) [17]. The aim is to identify the clinical 
relevance and feasibility of applying wearable motion sensing technology in these individuals and to 
reveal existing problems that have to be solved. In particular we aimed to clarify the following aspects: 
(a) to assess the quality and internal validity of studies using body-fixed sensors for measuring daily 
activity in patients with chronic diseases, (b) to provide an overview of ambulatory activity 
measurement tools used for chronic diseases and their properties, (c) to summarize the mode of 
application of different body-fixed sensors which measure individuals’ daily activity, (d) to sum up 
encountered problems and technical failures, (e) to assess user acceptance, and (f) to conclude about 
the clinical relevance. 
2. Methods 
Because of the large variety of chronic diseases, it was important to focus on some of the most 
frequently occurring chronic diseases for this review. Among the main chronic diseases [18] we 
selected Osteoarthritis, Cardiovascular Diseases (CVD), Typ-2-Diabetes mellitus and Chronic 
Obstructive Pulmonary disease (COPD) for this review. With these four types of chronic diseases three 
main domains of physical impairment that are influenced by these chronic illnesses can be covered: 
physiological problems (CVD&COPD), metabolic syndromes (Diabetes) and physical impairments 
(Osteoarthritis). Of all global deaths in 2005, 39% were because of these chronic diseases [1]. 
In March 2009 a librarian performed an electronic search on PubMed and the Physiotherapy 
Evidence Database (PEDro). The PubMed search strategy included the following keywords: (chronic 
diseases OR cardiovascular disease OR CVK OR diabetes OR diabetic OR COPD OR osteoarthritis) 
AND (gait disorder OR walking OR kinematic OR gait analysis system OR gait analysis device) AND 
(acceleromet* OR pedomet* OR gyrosco* OR wearable system OR activity monitor OR motion 
sensing OR instrumentation OR equipment) AND (physical activity OR motor activity OR activity). 
Because the PEDro database does not have a MeSH key terms registry, this search strategy was 
modified for this database. 
The search included all articles between January 1990 and March 2009 which were published in 
English or German. We only included articles with a randomized controlled trial design. To identify 
further studies, reference lists of primary articles were reviewed. 
2.1. First Selection Based on Abstracts 
Based on the title and abstract a first selection was performed. Papers were included in the full text 
review when they satisfied the following inclusion criteria: (1) Types of studies: only randomized 
controlled trials; (2) Types of participants: patients in the studies had one of the following diseases: 
Diabetes, Osteoarthritis, COPD or CVD; (3) Measurement tool: only trials evaluating mobility 
characteristics of individuals with wearable motion sensing technology that is intended for long-term 
monitoring under free living conditions were included (“wearable system”, “Accelerometer”, 
“Pedometer” or “activity monitor”). Laboratory-based analysis systems were excluded; Types of 
outcome measures: ICF categories “changing and maintaining body position” or “walking and Sensors 2010, 10                                       
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moving” had to be reported; Intervention: an intervention focussing on mobility/physical activity must 
be reported. 
Disagreement regarding inclusion of the studies was resolved by consensus between authors 
(RHK/KS). In case of disagreement between the two reviewers, a third person (EDB) decided whether 
the article should be included in the systematic review. 
2.2. Method for Quality Assessment in Selected Full Text Articles 
Quality assessment of the included articles was based on the PEDro scale [19,20] and independently 
assessed by two reviewers (KS&RHK or EDB). The PEDro scale is based on the Delphi list developed 
by Verhagen et al. [21], which is a set of 11 criteria for quality assessment: (1) eligibility; (2) use of 
randomization; (3) concealment of treatment allocation; (4) equivalence (or similarity) of groups at 
baseline; (5) blinding of the subjects; (6) blinding of the therapists; (7) blinding of the outcome 
assessors; (8) intention-to-treat analyses; (9) reporting of point estimates; (10) measures of variability 
of the primary outcome and (11) adequacy of follow-up and use of between-group statistical 
comparisons [22]. 
Every full text article was read by two independent reviewers (KS, EdB and RHK) and judged with 
the quality scale. Percentage agreement between raters and Cohen’s kappa were calculated with 
GRAPHPAD software (Version 2002–2005; GRAPHPAD Software Inc, San Diego, Ca), and were 
interpreted in accordance with Landis and Koch’s benchmarks for assessing the agreement between 
raters: poor (<0), slight (0.0 to 0.20), fair (0.21 to 0.40), moderate (0.41 to 0.60), substantial (0.61  
to 0.80), and almost perfect (0.81 to 1.0) [23]. Disagreement regarding inclusion of the studies was 
resolved by consensus between authors (RK, EDB, KS). As recommended by van Tulder et al. [24] a 
third reviewer (LA) was used in the event of any disagreement between the two reviewers regarding 
the methodological quality of a trial. The PRISMA-statement was followed for reporting items of this 
systematic review and meta-analyses [25]. 
3. Results and Discussion 
First Selection Based on Abstracts: 162 abstracts were identified with the search strategy. The title 
and abstract reading excluded 133 studies (Figure 1). None of the articles had to be excluded on the 
basis of a language problem. During the full text reading four further articles had to be excluded. 
Finally, 25 articles could be included in the quality judgement; two RCTs focussing on arthritis [26,27], 
four focussing on COPD [28-31], six focussing on CVD [32-37], and 13 focussing on Diabetes [38-50]. 
The three articles written by Kirk et al. [44,45,47] were all based on the same study and, therefore, 
treated as one publication. Although these three papers were focussing on different research questions, 
they essentially used the same set of data for the parameters of interest for this review. Table 1 gives 
an overview of all included studies with their corresponding PEDro-scores. 
Data Quality: The quality scores of studies ranged from 3 to 9 points out of a maximum of 11 points. 
The mean quality score was 6.3 ± 0.3 points. Both the median and mode values were 6 points (Table 1). 
The Kappa value was 0.91 (with 95%-confidence interval ranging between 0.87–0.96), indicating an 
agreement between raters considered to be ‘almost perfect’. Sensors 2010, 10                                       
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Figure 1. Flow diagram (Adapted from:  Moher, D., Liberati, A., Tetzlaff, J.,   
Altman, D.G., The PRISMA Group (2009). Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371 /journal.pmed1000097). 
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Table 1. Overview of studies. 
Author PEDRo 
Quality score
Osteoarthritis   
Talbot et al., 2003 [26]  6 
Toda et al., 1998 [27]  6 
COPD   
Bauldoff et al., 2002 [28]  6 
de Blok et al., 2005 [29]  6 
Sewell et al., 2005 [30]  6 
Steele et al., 2008 [31]  7 
CVD  
Coghill et al., 2008 [32]  8 
Hughes et al., 2007 [33]  7 
Moreau et al., 2001 [34]  7 
Sohn et al., 2007 [36]  5 
Witham et al., 2005 [37]  8 
Diabetes mellitus  
Araiza et al., 2006 [38]  6 
Bjorgaas et al., 2005 [39]  6 
Bjorgaas et al., 2008 [40]  5 
Engel et al., 2006 [41]  6 
Keyserling et al., 2002 [42]  8 
LeMaster et al., 2008 [48]  9 
Tudor-Locke et al., 2004 [49]  5 
Kirk et al., 2001 [46]  7 
Kirk et al. 2003, 2004 [44,45,47] 7/6/8 
Kirk et al., 2009 [43]  9 
Yates et al., 2008 [50]  4 
3.1. Technologies and Applications 
There were 15 studies that evaluated walking using a pedometer (step counters). Six studies used 
uniaxial accelerometers for activity measurements (e.g., by calculating the integral over the rectified 
accelerometer signal over a certain duration) to obtain overall measures of physical activity level 
and/or estimations of energy expenditure or step counts. Five studies used multiaxial movement 
sensors for long-term monitoring of activity patterns. No studies used methodologies (e.g., gyroscopes) 
to characterise either spatio-temporal parameters during long periods of walking or to evaluate 
characteristics of postural transitions or used combinations of uniaxial devices for posture detection. 
Two studies used a combination of a pedometer and an accelerometer for the determination of energy 
expenditure. The sum of reported methods is larger than 25. 
Three different applications could be identified: in 21 studies the wearable device was used to 
measure walking activity of patients. The wearable systems were also used as a study outcome 
measure (the number of steps, movements (accelerations of the body) or energy consumption at 
baseline and follow up were reported and compared). Pedometers were further used to encourage Sensors 2010, 10                                       
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patients increasing their physical activity-level (five studies) or for controlling their activity (three 
studies); see Section 3.4 for more details. For this purpose the wearable devices were used as a direct 
feedback, e.g., the device indicated the number of steps per day performed. Table 2 summarises the 
various wearable sensors with their properties and applications. Different instruments for measuring 
physical activity were used across the studies. The systems uncovered and their general characteristics 
are summarised in Table 2. 
3.2. Mode of Application 
Table 2 contains an overview of the types of devices that have been used with their properties and 
applications. In most studies the choice of instrument was either a pedometer or an accelerometer. Two 
studies used the combination of an accelerometer and a pedometer [26,48]. The majority of studies 
used devices that are attached at hip level. Two studies apply devices that should be attached to   
the ankle. 
Table 2. Body fixed sensors with their properties and applications. 
Device type  Outcome Measure(s)/Placement 
Pedometers 
Yamax Digi-walker Modell SW-200 [26,29,34,36,49,50],  
SW 700 [41], ML AW-320 [40], (Yamax, Tokyo, Japan),  
SW 701 [38] (New Lifestyles, Kansas City, MI) 
Step counts, distance, Energy 
Expenditure/Waist 
Sportline Distance Pedometer Model 342  
(Sportline, Campbell CA) [28] 
Distance/Waist 
Pedometer (Seiko, Tokyo, Japan)  
(no further specifications) [27] 
Step Counts/Waist 
Accusplit Eagle 170 (Pleasanton, CA) [48]  Step counts, distance, Energy 
Expenditure/Waist 
NL-800 (New Lifestyles, USA)  Step Counts/Waist 
Uniaxial Accelerometers 
Z80/32KV1 activity monitor  
(Gaehwiler Electronics; Hombrechtikon, Switzerland) [30] 
Activity counts/Waist 
Caltrac Accelerometer  
(Muscle Dynamics, Torrance, CA, USA) 
Energy Expenditure/Waist 
MIT Accelerometer Modell 7164  
(MIT, Shalimar, Florida, USA) [33] 
Activity counts/Ankle 
Computer Science and Applications (CSA) uniaxial 
Accelerometer, (Computer Science and Applications, Shalimar, 
Florida, USA) [44,45,47] 
Activity counts/Waist 
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Table 2. Cont. 
Multiaxial Accelerometers 
Step Activity Monitor (SAM) (Prosthetic Research Study, Seattle, 
WA, USA)/StepWatch Activity Monitor  
(OrthoCare Innovations, Washington DC) [48,63] 
Step counts, step rate/Ankle 
RT3 Accelerometer  
(Stayhealthy Inc, Monrovia, CA, USA) [31,37] 
Activity counts, vector magnitude, 
energy expenditure/Waist 
ActiGraph model GT1M (ActiGraph LLC, Pensacola, FL, 
USA)[43]; Manufacturing Technology, Fort Walton Beach, FL) [35] 
Step counts, activity counts, energy 
expenditure/Wrist, waist, ankle 
Tritrac-R3D (Hemokinetics, Madison, WI, USA)[26]  Activity counts, vector magnitude, 
energy expenditure/Waist 
3.3. Feasibility and Adherence 
Six studies reported difficulties and study limitations with wearable activity measurement tools. 
Three studies reported on adherence problems to wear the devices or to wear the devices in the proper 
measurement position [27,42,48]. One study suspected that differences between study groups became 
not apparent because of the high signal-to-noise-ratio of the devices used [31]. One study reported 
inconsistencies between self-report measures of physical activity and accelerometers. The 
inconsistencies were presumed to be caused by the wearable system [33]. One study remarked on the 
lack of being able to conclude about the intensities of the physical activities performed during the 
study period [34]. Table 3 gives an overview of the problems and limitations mentioned. None of the 
studies reported about user acceptance of the measurement tool. 
3.4. Clinical Relevance 
Completed studies where individuals or groups were followed up in time and where the effects of 
interventions on physical activity were investigated totalled 21 studies: two completed RCTs focussing 
on arthritis [26,27], four completed RCTs focussing on COPD [28-31], five RCTs focussing on   
CVD [32-34,36,37], and ten completed studies focussing on Diabetes [38-49] (where [44,45,47] were 
treated as being one study). The remaining studies were either published study protocols or presenting 
base line data only. 
Preferred reporting items [25] were derived from each included trial on: (1) characteristics of trial 
participants and the trial’s inclusion criteria; (2) type and aim of intervention; (3) type of mobility 
outcome measure (including the level of change in mobility outcome (using wearable systems); (4) 
conclusions from the studies. Because the interventions and reported outcome measures varied 
markedly, we focused on describing the studies and their results, and on qualitative synthesis rather 
than meta-analysis. 
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Table 3. Reported encountered problems and technical failures. 
Author Type/Brand  Problems  reported 
Toda et al.,  
1998 [27] 
Pedometer (Seiko, Tokyo, 
Japan) (no further 
specifications) 
Three of 18 participants in the control group (17%; see Table 1) had 
forgotten to attach pedometers for several days and were excluded 
from the study. The remainder of this group (n = 15) were 
evaluated [27]. 
Steele et al.,  
2008 [31] 
RT3 Accelerometer 
(Stayhealthy Inc., Monrovia, 
CA, USA) 
The RT3 data had a high signal-to-noise ratio that swamped any 
differences in daily activity between the groups. This finding was 
evidenced by large day-to-day variations in VMU (Table 2), further 
contributing to low power of the RT3 measurement of daily activity. 
The authors suspect that an arduous side-by-side comparison of the 
performance characteristics of the TriTrac-R3D and the RT3 might 
have shown that the TriTrac-R3D had a better signal-to-noise ratio, 
which would help explain why this device was able to detect subtle 
differences in daily activity in people who were exercising for 
greater durations. This was not done, because preventive 
maintenance and recalibration of the TriTrac-R3D units in 
possession of the authors were no longer available, and the TriTrac-
R3D could no longer be purchased [31]. 
Keyserling et al., 
2002 [42] 
Caltrac Accelerometer 
(Muscle Dynamics, Torrance, 
CA, USA) 
One limitation mentioned is possible bias in PA measurement, 
which may have resulted from differences in actual Caltrac wearing 
time by treatment group. This might indicate possible problems with 
compliance wearing the device. There were, however, no 
differences in reported wearing time between treatment groups. It is 
possible that the actual PA energy expenditure was underestimated 
by the Caltrac, since it does not detect non-ambulatory PA (e.g., arm 
swinging). However, this bias is consistent for all subjects and is a 
limitation in the use of vertically oriented accelerometers as a direct 
measure of PA [42]. 
Hughes et al.,  
2007 [33] 
Uniaxial MIT accelerometer, 
Modell GT1M 
(Manufacturing Technology, 
Fort Walton Beach, FL) 
The decline in total activity counts/week measured by 
accelerometers did not parallel the marked decrease in self-reported 
physical activity in the controls. The authors speculate that this 
discrepancy may be due to limitations of accelerometers since these 
devices cannot record water activities, activities that increase energy 
expenditure without a proportional increase in bodily acceleration 
(e.g., walking uphill) and those requiring a large amount of upper 
body movement (e.g., washing windows) [33]. The decrease in self-
reported activity in the controls could reflect a decline in these 
activities, which would not be detected by accelerometers. 
Moreau et al.,  
2001 [34] 
Yamax Digi-Walker, SW-200 
(Yamax, Tokyo, Japan) 
The authors were unable to determine the intensity of the amount of 
daily walking that the women included in the study performed [34]. 
LeMaster et al., 
2008 [48] 
StepWatch  
(OrthoCare Innovations, 
Washington) 
With respect to protocol adherence there were some participants that 
attached the StepWatch in the reverse direction causing loss of 
physical activity data [48]. 
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3.4.1. Characteristics of Osteoarthritis Studies 
Both osteoarthritis studies were randomised controlled trials published in English. The duration of 
the Talbot et al. study [26] was 24 weeks; 12 weeks for the intervention and an additional 12 weeks 
follow-up period. Toda et al. [27] report a 6-week study duration. The two included studies   
involved 74 participants with a mean age (SD) of 66.7 (SD 8.2) years. The main inclusion criteria 
entailed being aged 60 and older, pain in one or both knees on most days, difficulty performing at least 
one functional task because of pain, radiographic evidence of osteoarthritis (OA) [26], as well as adult 
obese women with a body mass index (BMI) >26.4 and a diagnosis of mild OA. One trial was 
conducted in the USA [26] and the other one in Japan [27]. 
The intervention received in Talbot et al. was 12 hours of the Arthritis Self-Management program 
over 12 weeks (received by both the control and intervention group). The intervention group received 
additional individualized instruction in the use of a pedometer, with the goal of increasing the step 
count by 30% of the baseline step count. The participants wore the three-axial Tritrac-R3D 
accelerometer and a non-sealed DigiWalker pedometer for 72 consecutive hours. The participants were 
given a physical activity goal and were receiving feedback about their physical activity through the 
instruction to record the daily steps taken at the end of each day of the measurement period [26].  
Toda  et al. [27] applied a weight control program in both groups. Group A received an appetite 
suppressant once per day plus a NSAID taken orally twice a day for 6 weeks (n = 22). At both 
breakfast and lunch 150 mL low calorie soup with essential nutrients were taken. Group B (n = 18) 
received the same NSAID for 6 weeks. Participants in both groups were instructed to walk 
continuously for up to 30 minutes each day. The participants wore a sealed pedometer (Seiko, Tokyo, 
Japan) for six weeks during working hours and leisure time. Results, recorded as steps per day, were 
checked in the clinic every two weeks.  
The primary outcome assessed was change in daily steps walked from baseline [26] and values of 
weight, BMI, percent body fat, change score, and metabolic correlates of obesity [27]. The effects of 
the physical activity interventions on daily walking yielded statistically significant results for change in 
daily step counts [26]. In this study the daily steps walked showed a significant group by-time 
interaction after controlling for age. From baseline to completion of training, a 23% increase in daily 
steps occurred in the intervention group and a 15% decrease in the control group. The participants in 
the intervention (walking exercise) group increased their pedometer steps/week on an average   
by 818 steps per day, compared to minus 680 steps/day in the self-management group (p = 0.04) [26]. 
Toda et al. claim to have effectively increased the number of steps taken per day in both groups, as 
compared to values of a reference population. This was a secondary outcome of their study and this 
claim was not, however, substantiated with data [27]. 
3.4.2. Characteristics of CVD Studies 
All five CVD studies were randomised controlled trials published in English. The duration of the 
studies was 12 weeks [32], 24 weeks [34], 26 weeks [36], 6 months [37], and 12 months [33], 
respectively. These five studies involved 272 participants with a mean age of 58.7 (SD 5.5) years. The 
main inclusion criteria entailed male non-smokers, with hypercholesterolemia [32], postmenopausal Sensors 2010, 10                                       
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women with borderline to stage 1 hypertension [34], adult African Americans with newly diagnosed 
hypertension [36], and patients with a clinical diagnosis of chronic heart failure [33,37]. 
The interventions received were the request to walk briskly for at least 30 minutes on at least five 
out of every seven days for a period of 12 weeks. In each exercise bout, energy expenditure was 
measured using a Caltrac accelerometer. Energy expenditure, duration of bout and rate of perceived 
exertion (RPE) were recorded in an activity log book. Intervention participants were trained to walk at 
an intensity equivalent of RPE of 12–14, which is equivalent to an energy expenditure of 5–7.5 kcal 
per minute. Control participants were requested to maintain their current activities of daily living. The 
aim was to investigate whether a home-based physical activity program meeting current guidelines was 
effective in improving the lipid profile in hypercholesterolaemic men [32]. Hughes and colleagues 
applied 11 weeks of supervised exercise (1-hour sessions, twice a week), medical evaluation, 
education and psychological support. The experimental group received an exercise consultation after 
baseline and 6-month assessments and a support phone call three months after each consultation. 
Control participants received a phone call on topics unrelated to exercise three and nine months after 
the baseline assessment. Outcome measures recorded at baseline were repeated at 6 and 12 months. 
The aim was to compare the long-term effect of the exercise consultation with standard exercise 
information on maintenance of physical activity and cardio-respiratory fitness [33]. Fifteen women in 
the exercise group of Moreau and co-authors walked three km·d
−1 above their daily lifestyle walking, 
whereas nine women in the control group did not change their activity. Walking activity was   
self-measured with a pedometer in both groups. Women in the EX group were provided with a target 
number of steps that would lead to a 3-km increase in daily walking. The target steps were added onto 
their baseline step value in order to prevent a decline in their current daily lifestyle activity. Women in 
the CON group were asked not to change daily activity and subsequently wore a pedometer for one 
week each month to document their walking. [34]. The intervention group of the Sohn et al. study was 
encouraged to walk an extra 30 minutes per day, five to seven days a week. The control group was not 
given this advice and received standard medical care. The researchers wanted to determine whether the 
encouragement of walking an extra 30 minutes a day decreases blood pressure in adult African 
Americans with newly diagnosed hypertension [36]. Witham and colleagues divided their exercise 
intervention into supervised and home phases. In the supervised phase (0 to 3 months), participants 
attended exercise classes as outpatients in groups of three to four, twice a week during the first three 
months. Between 17 and 20 sessions were offered during the 3-month period. Participants in the 
control group received usual care. The aim was to determine whether a seated exercise program 
designed specifically for older frail patients with heart failure (HF) would be well attended and would 
lead to improvements in exercise capacity, everyday activity, and health status [37]. 
Physical activity was measured using the Caltrac accelerometer set to display physical activity 
energy expenditure (kcal). Participants recorded wear time, total activity energy expenditure and any 
bouts of moderate activity ≥30 minutes or vigorous activity of ≥20 minutes each day in a diary. 
Accelerometers were worn by all participants for one week prior to randomization to establish baseline 
physical activity and throughout the 12-week experimental period [32]. Participants wore the uniaxial 
MTI accelerometer model 7164 (MTI, Shalimar, Florida, USA) on their right ankle during all waking 
hours for seven days, except during water activities. Accelerometers were set to record activity   
in 1-minute epochs. Activity counts/min recorded over the seven monitored days were summed to Sensors 2010, 10                                       
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produce total activity counts/week [33]. Subjects were given a Yamax SW-200 pedometer (Yamax, 
Inc., Tokyo, Japan) to wear throughout the day for a 1- to 2-week period before beginning the 24-week 
walking program in order to document pre-intervention daily lifestyle walking activity. An average 
daily value was computed and served as the baseline value. Stride length was measured of each subject 
and walking distance was calculated [34]. All subjects in the Sohn et al. study used a Yamax SW-200 
pedometer (Yamax, Inc., Tokyo, Japan) to record the number of steps walked on a daily basis [36]. 
Daily activity over a 7-day period was measured using the Stayhealthy RT3 triaxial accelerometer 
(Stayhealthy Inc, Monrovia, California). The device was mounted anteriorly on the participant’s 
waistband and recorded summed acceleration counts at 1-minute intervals [37]. 
Participants in the intervention group performed 97.6% of the frequency of walking requested and 
expended 120% of the intensity of walking requested. They used a mean of 1,675 kcal per week 
carrying out the walking program, but showed a reduction of 12% (p < 0.01) in net energy expenditure 
at the follow-up. The control group showed a non-significant reduction in net energy expenditure  
of 5% (p = 0.08), compared to baseline values [32]. Total activity counts/week measured by 
accelerometry did not change significantly from baseline to 6 months (98%) and 12 months (98%) in 
the experimental group. In the control group, total activity counts/week decreased non-significantly 
from baseline to 6 and 12 months by 5.2% and 8%, respectively [33] At baseline, women in the EX 
and CON groups walked an average of 5,400 ± 500 and 7,200 ± 700 steps·d
−1, respectively, equivalent 
to walking 3.4 ± 0.3 and 4.7 ± 0.4 km·d
−1 (significantly different between EX and CON groups,  
p < 0.05). Women in the EX group increased their daily walking by 4,300 steps (2.9 ± 0.2 km·d
−1; 
significantly different from baseline and from the CON group, p  < 0.05) and averaged a total   
of 9,700 ± 400 steps·d
−1 (including baseline steps) across the 24-week walking program (significantly 
different vs. the CON group). The women in the CON group did not change their walking activity  
over 24 weeks (−0.3 ± 0.3 km·d
−1). In this study, pedometers were used to help the women achieve 
their walking prescription and it was documented that women were increasing walking activity from 
their usual daily lifestyle walking with this approach [34]. Sohn et al. report that both the intervention 
and control group increase their daily steps, however, they do not report data that substantiate this 
observation. The authors assume that an explanation of this finding lies in the fact that in both groups 
the pedometer acted inadvertently as a motivator for walking [36]. The most important finding in the 
Witham study was the significant increase in everyday physical activity measured by accelerometry in 
the exercise group at six months. The increase in everyday activity was most likely to have resulted 
from behavioral changes brought about by participation in the program, telephone follow-up, keeping a 
diary, and the setting of walking targets [37]. 
3.4.3. Characteristics of type 2 Diabetes Mellitus Studies 
All type 2 Diabetes mellitus studies were randomised controlled trials published in   
English: three trials from the UK [43-47], three trials from the USA [38,42,48], two from   
Norway [39,40], one from Australia [41], and one from Canada [49]. The duration of the studies  
was 5 weeks [46], 6 weeks [38], 12 weeks [39], 24 weeks [49], 6 months [40,41,44,45,47],  
and 12 months [42,43,48], respectively. These ten studies involved 720 participants with a mean age  
of 57.3 (SD 8.5) years. The main disease related inclusion criteria entailed type 2 diabetes [38,40,42-47], Sensors 2010, 10                                       
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type 2 diabetes and overweight [39], type 2 diabetes, overweight/obese and sedentary subjects [41,49], 
and people with diabetic peripheral neuropathy [48]. 
Kirk et al. (2001) applied an exercise consultation and standard exercise information (experimental) 
or standard exercise information alone (control). The aim was to evaluate the effect of exercise 
consultation on promotion of physical activity in people with type 2 diabetes. The outcomes were stage 
of exercise behaviour, physical activity levels (7-day recall questionnaire & accelerometer), and 
quality of life. The intervention did not include a physical activity target and no feedback about 
physical activity was provided to the participants from the accelerometer [46]. Araiza and   
colleagues (2006) randomized patients into two groups after 10 days of baseline activity. The control 
group (n = 15) was instructed to continue with their baseline activity for six weeks. The active group 
(n = 15) was instructed to walk at least 10,000 steps per day, five or more days per week, for six 
weeks. The authors wanted to determine whether a recommendation to walk 10,000 steps per day 
would result in significant improvements in glycemic control, insulin sensitivity, and cardiovascular 
risk in patients with type 2 Diabetes mellitus. Subjects in the active group received feedback from a 
pedometer [38]. In the study of Bjorgaas et al. (2005) participants in the exercise group were offered  
a 12-week program of 2 × 1.5-h supervised exercise per day. This program did not include a specific 
physical activity target. The control group was not given any specific recommendations concerning 
physical activity. The aim was to investigate the relationship between pedometer-registered activity, 
aerobic capacity (VO2max) and self-reported activity and fitness. Pedometers were given to the 
patients with the instruction to wear the devices during three consecutive weekdays [39]. In the   
UK-based intervention that resulted in three different papers [44,45,47] the focus of the intervention 
was exercise consultation, based on the transtheoretical model, combined motivational theory and 
cognitive behavioral strategies into an individualized intervention to promote physical activity. The 
aim of the consultation was to encourage participants to accumulate 30 minutes of moderate physical 
activity most days of the week. There was no target goal set for physical activity besides the time limit. 
The aim of this project was to evaluate the long-term (6 and 12 months) effectiveness of physical 
activity counseling in people with type 2 diabetes [44,45,47]. Bjorgaas and co-workers (2008) wanted 
to investigate whether the use of a pedometer increases walking and/or enhances beneficial outcomes 
in an intervention study aimed at physical activity. Study participants were allocated to a pedometer or 
no pedometer group. All were encouraged to increase walking. Subjects in the pedometer group 
registered pedometer steps at three days, twice per month for six months, and were encouraged to 
increase their daily step count based on the mean number of steps during month 1. Participants who 
did not use a pedometer were encouraged to increase the average daily time spent walking guided by a 
logbook. There were no fixed target goals set for participants [40]. To investigate the impact of using a 
pedometer on time spent walking in a coaching intervention was the aim of Engel and her group. For 
that purpose participants were allocated to either a pedometer and coaching (intervention) group or a 
coaching-only (control) group. Coaching for both groups involved education, goal setting, and 
supportive/motivational strategies to increase time spent walking. The goal setting to achieve the 
physical activity goals differed between the groups: the pedometer group set goals based on the 
number of steps per day, while the other group set goals based on a certain amount of time spent 
walking each day [41]. The study of Tudor-Locke et al. (2004) examined the effectiveness of the First 
Step Program (FSP). In addition to the primary outcome of physical activity (measured as steps/day), Sensors 2010, 10                                       
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the authors also examined whether increased physical activity was related to improvements in 
cardiovascular health, glycemic control and lipid profiles. During an adoption phase (initial four 
weeks), participants were asked to attend four weekly group meetings (individual attendance was 
recorded). They were given pedometers and the program manual containing goal setting and   
problem-solving exercises, as well as calendars for self-monitoring steps/day. No specific advice was 
given concerning diet or glycemic control. During the adherence phase (subsequent 12 weeks), 
participants were asked to use their pedometers (as a feedback tool) and calendars for goal-setting and 
self-monitoring. The control group was individuals on a waiting list [49]. To determine the effect of a 
lower extremity exercise and walking intervention program on weight-bearing activity and foot ulcer 
incidence in people with Diabetes Mellitus (DM) and Peripheral Neuropathy (PN) was the aim of 
another study. Intervention components included leg strengthening and balance exercises; a graduated, 
self-monitored walking program (part 1); and motivational telephone calls every two weeks (part 2). 
Participants were encouraged to increase activity by adding a minimum of 100 steps to their daily 
activities every two weeks. They self-monitored walking with an Accusplit Eagle 170 pedometer as a 
self-motivating means. The control group did not receive guidance to undertake walking. Both groups 
in this study received diabetic foot care education, regular foot care, and eight sessions with a physical 
therapist. [48]. Keyserling and co-workers (2002) wanted to determine whether a culturally appropriate 
clinic- and community-based intervention for African-American women will increase moderate-intensity 
physical activity. Three treatment conditions were: clinic and community (group A), clinic only (group 
B), or minimal intervention (group C). The clinic-based intervention (groups A and B) consisted of four 
monthly visits with a nutritionist who provided counseling to enhance PA and dietary intake that was 
tailored to baseline practices and attitudes; the community-based intervention (group A) consisted of 
three group sessions and 12 monthly phone calls from a peer counselor and was designed to provide 
social support and reinforce behavior change goals; and the minimal intervention (group C) consisted 
of educational pamphlets mailed to participants. Participants were encouraged to increase the 
“minutes” (duration) of moderate or vigorous activities or to add intensity to mild/sedentary   
activities [42]. Participants were randomized to receive a physical activity consultation delivered by a 
person or in written form to increase physical activity levels over 6 and 12 months in a UK-based 
study. The aim was to compare the effectiveness of two methods of physical activity promotion for 
people with type 2 diabetes, in contrast to standard care. The intervention part did not include physical 
activity target formulation or goal setting [43].  
Kirk et al. (2001) assessed physical activity with a uniaxial accelerometer (CSA Inc; no further 
specifications) that delivered activity counts at one-minute intervals for a seven-day period. Upon 
return, activity monitors were downloaded and a total weekly physical activity count was calculated 
for each participant [46]. In the Araiza et al. study each subject wore a Yamax Digiwalker step counter 
(SW-701, New Lifestyles, Kansas City, MI) throughout the day, except for sleeping and bathing, and 
was trained regarding proper placement and use of the pedometer. Each morning the pedometer was 
reset to zero, and each evening the subject recorded the steps accumulated during the day in an activity 
log [38]. Bjorgaas et al. (2005) gave their participants a pedometer (Yamax Digi-Walker ML AW-320, 
Yamax, Tokyo, Japan) and these were instructed to wear it clipped to their clothing or belt at the waist, 
centred over the foot. Each participant registered his ambulatory activity by pedometer during three 
consecutive weekdays. Participants were instructed to set the pedometer to zero at the beginning of the Sensors 2010, 10                                       
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first day and to record the number of steps each evening. All participants completed the registration 
satisfactorily [39]. The primary outcome measure in the three studies from the Kirk group [44,45,47] 
was measurement of bodily acceleration from a CSA uniaxial accelerometer (Computer Science and 
Applications, Shalimar, FL). Monitors were worn for seven days during waking hours. Monitors were 
downloaded on return and a total weekly activity count was calculated. Thus, patients did not receive 
direct feedback from the monitors about their physical activity. Bjorgaas et al. (2008) used a Yamax 
Digi-Walker three weekdays twice per month to register ambulatory activity [40]. Changes in cardio 
respiratory fitness and anthropometric measurements were used to corroborate changes in physical 
activity. A Yamax-Digi-Walker was used to measure steps per day in the intervention group of   
Engel et al. Participants were instructed to reset the pedometer to zero each morning before positioning 
it on their waistband [41]. Tudor-Locke and colleagues assessed physical activity (defined as 
steps/day) with a Yamax SW-200 pedometer over three consecutive days while engaging in usual 
activities. Each person was instructed to set the pedometer to zero the first morning, and then seal the 
cover with a sticker, thus preventing feedback from the pedometer during the measurement phase [49]. 
Physical activity as a primary outcome was assessed with a StepWatch accelerometer. Changes in total 
daily steps, steps taken in 30-minute exercise bouts, and minutes per week were assessed [48].   
Keyserling et al. assessed physical activity by Caltrac accelerometer to objectively measure physical 
activity energy expenditure. There were no devices used to give feedback on physical activity [42]. 
The primary outcome of the King et al. (2009) study was physical activity derived from the ActiGraph 
GT1M accelerometer. This device delivered weekly step counts and body accelerations per minute and 
were worn for seven days [43]. The device was not used as a feedback or motivational tool.  
Physical activity counts/week increased by 4% in the experimental group and decreased by 9% in 
controls. A significant difference was recorded for the change in activity counts per week from 
baseline to follow-up between the experimental and control group [46]. The main finding of Araiza’s 
group was that subjects in the active group significantly increased physical activity by 69% during the 
intervention phase of the study, whereas there was no change in the physical activity of the control 
group. The authors attributed this increase to the use of the pedometer [38]. Bjorgaas and   
colleagues (2005) observed that both exercise and control groups tended to increase pedometer   
activity [39]. The experimental group in the study of Kirk et al. had increased levels of physical 
activity from baseline to six months, with no decrease from 6 to 12 months. In the control group, 
accelerometer counts per week decreased from baseline to 12 months. Between-group differences were 
recorded in physical activity (recall and accelerometer) at 12 months. Experimental participants 
significantly increased total activity. Control participants recorded no significant change [44,45,47]. In 
the pedometer group of Bjorgaas et al. (2008), the number of steps per day did not increase from 
month 1 to month 6. The authors concluded that the use of a pedometer did not increase walking or 
enhance beneficial metabolic outcomes. They suspect that an increase in step count may be attributed 
to regular counselling and goal setting, and not to the use of a pedometer per se [40]. Engel et al. (2006) 
observed with an ANCOVA approach that group membership had no influence on the time spent 
walking. Sedentary older adults were able to achieve the physical activity targets with a coaching 
intervention equally well as with an added pedometer. The authors acknowledge, however, that the 
pedometer group focussed on steps per day, and thus they also included steps made during incidental 
bouts of activity in their analysis, whereas the coaching group focused on time spent   Sensors 2010, 10                                       
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walking [41]. Intervention (with step goal) participants increased their physical activity by   
approximately 3,000 steps/day from baseline (p < 0.01), which was a significant improvement relative 
to the waiting list controls (p < 0.0001). At 24 weeks follow-up the difference between groups was no 
longer significant [49]. At 6 months, bout-related daily steps increased 14% from baseline in the 
intervention group and decreased 6% from baseline in the control group. Although the groups did not 
differ statistically in the change in total daily steps, steps had decreased by 13% in the control group  
at 12 months [48]. For the primary study outcome, the comparison of PA levels during 0.5 and 1 year 
of follow-up, there was a significant difference between group A und C after 12 months and between B 
and C following six months. One limitation mentioned is a possible bias in PA measurement, which 
may have resulted from differences in actual Caltrac wearing time by treatment group [42].   
Kirk et al. (2009) observed no significant interaction between time and group in accelerometer counts, 
step counts, and time in moderate intensity or above, over 6 and 12 months. There was a significant 
main effect of time on accelerometer counts (P < 0.001), step counts (P = 0.005), time in moderate 
intensity or above (P = 0.006) and the 7-day recall (P = 0.007), with an overall decrease between 
baseline and 12 months (P < 0.01) and 6 and 12 months (P < 0.01) across all measures of physical 
activity. Neither a theory-driven physical activity consultation delivered by a person nor in written 
form were better than a standard care leaflet at increasing physical activity levels over 6 and 12 months 
in the full study group [43]. 
3.4.4. Characteristics of COPD Studies 
The four COPD studies were randomised controlled trials published in English; two trials were 
conducted in the USA [28,31], one in the UK [30], and one in the Netherlands [29]. The duration of 
the studies was 7 weeks [30], 8 weeks [28], 9 weeks [29] and one year [31], respectively. These four 
studies involved 331 participants with a mean age of 66.9 (SD 9.3) years. The main disease-related 
inclusion criteria entailed diagnosis of COPD [28-30] or self-reported diminished physical functioning 
related to a pulmonary problem or pulmonary function impairment [31]. 
Experimental group subjects were instructed to walk at their own pace for 20 to 45 min, two to five 
times a week, using distractive auditory stimuli (DAS) with a portable audiocassette player in the 
Bauldoff et al. study [28]. The control group received the same instructions, but no DAS. All subjects 
recorded the distance and time walked using self-report (pedometers and daily logs). The aim was to 
determine if DAS in the form of music would promote adherence to a walking regimen following 
completion of a pulmonary rehabilitation program (PRP) and, thereby, maintenance of gains achieved 
during the program. Primary outcome measures were perceived dyspnea during activities of daily 
living (ADL) and 6-min walk (6 MW) distance [28]. De Blok et al. instructed their experimental group 
to follow a regular rehabilitation program plus an additional lifestyle physical activity counseling 
intervention. They also received direct feedback from a pedometer. The control group followed a 
regular COPD rehabilitation program only. In the control group, patients wore the pedometer 1 week 
prior to the rehabilitation and 1 week during week 9 of their rehabilitation. Patients in the experimental 
group wore the pedometer for 10 weeks (1 week prior to rehabilitation and 9 weeks during 
rehabilitation). Patients were instructed to wear the pedometer over the course of the entire day until 
going to bed, and to record daily step counts in a diary. Patients also recorded in their diary at which Sensors 2010, 10                                       
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time they put the pedometer on and at which time they put the pedometer off. [29]. The aim of this 
intervention was to stimulate patients to increase their daily physical activity level by incorporating 
lifestyle physical activities into daily life. Patients received exercise counseling in order to motivate 
them to enhance physical activity in daily life and wore a pedometer in order to monitor changes in 
physical activity behavior. The pedometer was used as a motivational and feedback tool [29].   
Sewell et al. randomized patients to a conventional 7-week general exercise program or an individually 
targeted exercise program. Daily activity was measured using ambulatory activity monitors. This 
group aimed to establish whether pulmonary rehabilitation (PR) improves domestic function and daily 
activity levels in COPD and whether individually targeted exercise is more effective than general 
exercise. The authors did not formulate specific physical activity goals [30]. Steele and co-workers 
applied a 12-week adherence intervention (weekly phone calls and home visit) including counseling on 
establishing, monitoring, and problem-solving in maintaining a home exercise program. The authors 
wanted to evaluate the effectiveness of an exercise adherence intervention to maintain daily activity, 
adherence to exercise, and exercise capacity over one year after completion of an outpatient pulmonary 
rehabilitation program. The control group consisted of continuing care with the referring provider and 
individual recommendations for continuation of the exercise program. Primary outcomes were daily 
activity, self-reported daily exercise, and functional capacity. The experimental group received a 
digital pedometer (no details specified) for self-monitoring and an exercise handbook describing 
aspects of the program. There was no goal setting for the physical activity and there was no feedback 
about physical activity from the accelerometer [31]. 
Following baseline testing, all subjects were given and instructed in use of an electronic pedometer 
(Model 342; Sportline; Campbell, CA), which measured walk distance to 1/100 of a mile precision [28]. 
In addition, all subjects were instructed in completion of a log, which included date, amount of time, 
and distance walked as measured by the electronic pedometer. There were no specified target goals, e.g., 
increase of walking, for the participants. The pedometer was rather used as a recording device and not 
as a feedback tool [28]. The cumulative distance walked by the DAS group was 19.1 ± 16.7 miles 
compared to 15.4 ± 8.0 miles for the control group, a 24% difference. Despite this difference, self-report 
exercise log data were similar for the two groups [28]. The primary outcome measure was daily 
physical activity and was measured by the Yamax Digi-Walker SW-200 (Tokyo, Japan). Mean 
steps/day was evaluated and patients were asked to set a goal for seeking their maximal physical 
activity limit once (measured in numbers of steps). The fourth counseling session was carried out in 
week 7 of the rehabilitation and dealt with consolidation of physical activity behavior. Patients were 
asked to set a goal for their personal physical activity norm, which should be between their mean 
steps/day until then and their maximal number of steps [29]. The overall amount of daily activity was 
measured as primary outcome by Sewell et al. using a uniaxial ambulatory activity monitor   
(Z80—32k V1 Int; Gaehwiler Electronics; Hombrechtikon, Switzerland). All of the patients wore the 
monitor on two consecutive days for a period of 12 hours on each day. Patients did not receive 
feedback from the device and it was not used as a motivational tool [30]. Physical activity when awake 
was measured as body movement in vector magnitude units (VMU) using the RT3 accelerometer on 
four 6-day measurements at home. An average of the daily activity in VMU performed over the six 
days was computed [31]. Sensors 2010, 10                                       
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Subjects who used DAS while walking had improved functional performance and decreased 
perceptions of dyspnea [28]. The compliance of recording daily step counts in the dairy turned out to 
be very high; 91.7% during pretest and posttest in experimental and control group and 95.5% during 
the 10 weeks that the experimental group wore the pedometer. There were no significant differences in 
the mean time of wearing the pedometer during the day between experimental group (13.1 hour/day) 
and control group (13.8 hour/day). The experimental group increased their mean steps/day   
by 1,430 steps/day (+69%) for six days without rehabilitation, whereas the control group showed an 
increase of 455 steps/day (+19%). The difference in pretest and posttest between the experimental and 
control groups was clinically relevant. De Blok et al. study showed that the number of steps/day 
increased after nine weeks of rehabilitation. The additional lifestyle physical activity counseling 
program with feedback of a pedometer showed a clinically relevant increase in steps/day [29]. 
Statistically significant percentage improvements were noted in both training groups. An increase in 
activity monitor counts of 29.18% was demonstrated by the GEP and of 40.63% by the ITEP. The 
authors acknowledge that a possible weakness of the study was that the goal direction may not have 
been sufficiently explicit in order to affect any change in the identified functional goals of the subjects. 
They also remark that the monitors utilized in this study only record the quantity of daily activity, and 
they do not provide any information relating to individual domestic task completion [30]. Steele et al. 
observed that no statistically significant difference between the intervention and control groups of 
daily activity at completion of the adherence intervention (short term) existed (p > 0.20). Neither were 
there significant differences between the intervention and control groups after one year. The authors 
remarked that a factor that may explain the lack of differences between the intervention and control 
groups in the accelerometer measure of daily activity was the finding that the RT3 data had a high 
signal-to-noise ratio that swamped any differences in daily activity [31]. 
3.5. Discussion 
Our quality evaluation of included papers yielded good to excellent correspondence between 
reviewers. In general, the scores ranged from low to high. This can be explained by the fact that four of 
the included papers were ongoing studies that presented baseline data only. There were ten randomised 
studies with a score above six points. The articles from the Kirk et al. group that were considered as 
being one study inconsistently reported the Pedro quality items. This resulted in different Pedro scores. 
The item “blinding” certainly negatively influenced the appraisal of the study quality. None of the 
articles fulfilled the criteria about blinding, an issue known to be quite impracticable in most clinical 
intervention studies. 
Pedometers or accelerometers were used for three different applications: (a) to measure the 
individuals’ activity behaviour, (b) to encourage subjects to increase their activity-level or (c) to 
control individuals’ activity level by using a direct feedback. In order to assess individuals’ activity 
level authors either assessed the subjects’ covered walking distance, the number of steps, or the energy 
consumption. The results of our review indicate that the used devices were suitable for verifying 
whether someone achieves his/her personal physical activity goal. This was especially the case in 
studies that used devices that allowed a direct feedback on performance. However, the use of 
pedometers, with the aim to encourage people to increase their activity and compare these to control Sensors 2010, 10                                       
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groups, seems questionable. Our findings show conflicting results in this regard. The devices used are 
not always able to differentiate between exercise and control groups when only subtle differences 
between groups exist. This can, of course, partly be explained by the lack of credibility of the 
interventions applied. However, some authors explicitly state that they think their findings are in part 
attributable to the disappointing measurement characteristics of the accelerometer used [31].   
Bravata et al. evaluated the association of pedometer use with increasing physical activity, and they 
suggest that the use of a pedometer is associated with significant increases in physical activity and 
significant decreases in body mass index and blood pressure [51]. Our findings add to this knowledge 
that the feasibility of wearable motion sensing technology also seems to relate to the reliability of the 
used devices in unsupervised measurement settings with the various studied individuals. However, 
there are also studies that find that subjects who used a pedometer did not increase walking during the 
study and health benefits were not enhanced by the use of a pedometer, e.g., Bjorgaas et al. (2008) [40]. 
This finding seems to contrast with studies that showed that the use of a pedometer leads to an increase 
in step counts [38,49]. The difference between these studies might be attributed to the inclusion of 
regular counselling and goal setting that leads to an increase in step count and not to the use of a 
pedometer per se. This assumption is in line with the results of a review on physical activity 
interventions to improve walking in cancer survivors [52]. The review concluded that goal setting 
combined with feedback from a pedometer and counselling are the likely factors that explain increases 
in physical activity. There is, thus, increasing evidence that the definition of a step goal may be the key 
motivational factor in increasing physical activity [51]. Together the results of these studies suggest 
that daily walking activity is likely to improve only when a realistic step goal is defined. 
Not all devices have the same accuracy for all different application fields. The Yamax Pedometer 
for example, a device currently used in clinical trials, seems to enable precise and reliable   
data [53,54]. However, Crouter et al. [55] showed that the spring-levered pedometer (Yamax 
Digiwalker SW-200) became less accurate with increasing BMI, increasing waist circumference, and 
greater pedometer tilt, whereas a piezoelectric pedometer (New Lifestyles NL-2000) was not affected 
by these variables. They thus concluded that in overweight and obese individuals, a piezoelectric 
pedometer is more accurate than a spring-levered pedometer especially at slower walking speeds [55]. 
Such a finding may guide the selection of a wearable system for certain chronic diseases that often 
present themselves with concurrent overweight of subjects, e.g., diabetes mellitus. However, no 
relationship between the type of the chronic disease and the type of the assessment tool could   
be identified. 
The number of reported problems or technical failures is small. This may indicate that body-fixed 
sensors for measuring daily activity in form of pedometers and accelerometers are good and reliable 
measurement instruments. The devices seem to be technically mature. Pedometers afford an 
inexpensive objective measure of physical activity. They are normally worn at the belt line and are 
sensitive to vertical movement [56]. Pedometers are designed to detect the total number of steps taken, 
distance travelled and energy expenditure. In most of these electronic devices, a horizontal   
spring-suspended lever arm deflects during movement with the acceleration of the hips [56]. The main 
limitation of waist-attached pedometers is, however, that the accuracy at slow walking speeds is 
reduced. The vertical accelerations of the waist are less pronounced during slow walking and cause an 
inaccuracy in measuring the steps [53,57,58]. In addition, pedometers are not able to assess intensity, Sensors 2010, 10                                       
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frequency and duration of activity [57]. The majority of the studies in this review did not consider 
these limitations. 
Most commercially available accelerometers are, as this review also reflected, waist-worn devices 
that measure body movements in terms of acceleration [57,59]. The majority of accelerometer sensors 
are sensitive to movement in the vertical plane, but some of them detect accelerations also in the 
antero-posterior and/or medio-lateral planes [60]. In contrast to pedometers, accelerometers are 
capable of describing intensity, frequency and duration of physical activity [57]. The major drawback 
of such waist-fixed accelerometers is that they seem to be affected by multiple factors such as 
movement style, gait speed, and mode and location of attachment [57,59,61,62]—a finding that 
potentially has implications for applications in individuals with chronic diseases. To overcome the 
limitations of the previous waist-attached devices, two-dimensional microprocessor-based 
accelerometers (e.g., the Step Activity Monitor, SAM) were developed [59,62] and used in two studies 
reviewed [48,63]. The SAM is an ankle-worn instrument and designed to detect movements of the 
lower extremity. It can objectively measure the amount, the pattern and also the intensity of activity 
and has adaptable sensitivity settings. The step activity monitor is able to record different activities 
such as walking, running, stair use, and bicycling [64]. Additionally, human steps can be detected by 
SAM for a wide variety of gait styles and walking pace [11,62].  
All studies included in this review assess mobility as walking and moving (ICF d450-d469). RCTs 
that assess mobility as changing and maintaining body position (ICF d410-d429) in individuals with 
chronic diseases were not identified. There were for example no studies that used wearable systems to 
characterise either spatio-temporal parameters during long periods of walking or those that evaluated 
characteristics of postural transitions. Neither were combinations of uniaxial devices for posture 
detection used. This finding has meaning in relation to an additional limitation of most commercially 
available activity monitors: they are not able to measure static movements such as standing and sitting. 
New emerging activity monitors, for example Physilog [65] and ActivPAL [60], have been developed 
with the aim of providing information about body postures. Physilog and ActivPAL can divide human 
activity into lying, sitting, standing and walking. ActivPAL furthermore offers information on step 
count and metabolic equivalents to each activity [66,67]. The observation seems justified that more 
research is necessary in individuals with chronic conditions to determine whether postural detection 
systems are an appropriate instrument for long-term measuring of physical activity in such individuals. 
Especially an understanding of the quantity and quality of physical (in)activity seems particularly 
important in addressing rehabilitation needs [65], e.g., for assessment and intervention procedures. 
The focus on mobility that we had—we limited the scope on “changing and maintaining body 
position (ICF d410-d429)” or “walking and moving (ICF d450-d469)” [17]—can be considered as a 
limitation of our review. Additional functions and sensations of the cardiovascular and respiratory 
system (ICF b450-b469) are measurable with wearable systems as well, e.g., with an ActiHeart   
device [68-70]. Information from this or from comparable systems, where activity and heart rate are 
measured next to calculations of energy expenditure for ambulatory activities, provides additional 
means of PA assessments. Such additional information has relevance for individuals with chronic 
diseases. It might well be that focusing on these additional functions and sensations of the 
cardiovascular and respiratory system (ICF) might have led to additional relevant studies. Sensors 2010, 10                                       
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The patients suffering from one of the selected chronic diseases do generally not need a permanent 
stationary treatment. These patients live at home and perform their usual daily occupation. Thus, it is 
important to assess their activity level in their living environment. Wearable technology allows 
clinicians to gather data where it matters the most to answer this question, i.e., the home and 
community settings. A wearable motion sensing system is likely to be operationally feasible if it meets 
the ‘needs’ and expectations of both the developer and user, where user can be either defined as study 
participant or clinical professional assessing subjects. User acceptance is thus an important determinant 
of operational feasibility [11]. This review could not exhaustively describe the technical failures and 
individuals’ acceptance as initially intended. The included studies did not extensively report on this 
issue. It is unlikely, however, that all patients readily accept a wearable system. The user issues 
identified include forgetting to put the device on, complying with the intended wearing time, and 
adhering to the application protocol of the device. Future studies should also include information on 
these aspects of wearable devices. 
Finally it has to be noticed that a particularly high number of articles considering patients with 
diabetes (10 completed studies and one ongoing study) and patients with CVD (6 articles; 5 completed, 1 
ongoing project) could be identified. Only few articles considered patients with COPD or 
osteoarthritis. It may be that the high prevalence of patients with diabetes influenced this result. 
Furthermore, the importance of regular physical activity is particularly recommended in patients with 
metabolic diseases. There is uncertainty, however, as to what the best treatment for osteoarthritis is.  
A critical appraisal shows that the overall quality of existing treatment guidelines is sub-optimal, and 
consensus recommendations are not always supported by the best available evidence [71]. Although 
there is outstanding evidence for the benefit of exercise therapy in knee osteoarthritis, there is at the 
same time some indication that exercise is underused as a treatment modality for this chronic   
condition [72]. The findings of this review seem to substantiate this indication. 
3.6. Other Reviews 
There are several other reviews that explore the potential of wearable motion sensing technology. 
The majority of these reviews are, however, non-systematic and narrative in nature and often confined 
to accelerometers only [73,74], focussing on a specific disease [75] or on the (older) adult population 
at large [11,76-78]. One systematic review investigates the validity aspects of using pedometers in 
investigating physical activity [79], one systematic review is focussing on COPD patients [80], and 
one systematic review investigates the use of pedometers to increase physical activity in adult 
outpatients [51]. 
4. Conclusions 
The number of studies that use pedometers (step counters) and/or accelerometers to obtain overall 
measures of physical activity level, or estimations of energy expenditure, form the majority when 
subjects with chronic disease conditions are studied. In contrast, the number of studies that use 
movement sensors for long-term monitoring of activity patterns, such as postural transitions or time 
spent in certain positions or activities, is nonexistent on the RCT level of study design. Sensors 2010, 10                                       
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Identified feasibility and adherence aspects of wearable motion sensing technology mainly relate to 
the signal-to-noise-ratio of some devices in unsupervised measurement settings and (to the) 
compliance to the application protocol of the devices by the various studied individuals. Information 
about the user acceptance when attached to certain body parts or clothing, which impedes 
measurements, is not available from the studied RCTs. 
Although feasible methods are available for monitoring activity patterns and posture detection, 
these methods have not yet been applied on a large scale in individuals with chronic conditions. 
Evidence-based clinical applications of these methods (e.g., for fall prediction and outcome 
assessment) are in need of (further) development. At present, therefore, the use of wearable systems 
for monitoring movement activities in people with chronic conditions has not yet reached its full 
potential. Our findings indicate that the challenge for the various developed wearable motion sensing 
systems is evaluation in “real life” settings. 
Before selecting a wearable motion sensing technology clinical practitioners should judge the 
psychometric properties of the desired device, estimate the feasibility of using the technology for the 
intended population, and formulate clear goals of measuring physical activity in clinical settings in 
order to receive credible information. 
References 
1.  Beaglehole, R.; Ebrahim, S.; Reddy, S.; Voute, J.; Leeder, S. Prevention of Chronic Diseases: A 
Call to Action. Lancet 2007, 370, 2152-2157. 
2.  Yach, D.; Hawkes, C.; Gould, C.L.; Hofman, K.J. The Global Burden of Chronic Diseases: 
Overcoming Impediments to Prevention and Control. JAMA 2004, 291, 2616-2622. 
3.  Johnson, R.J.; Wolinsky, F.D. The Structure of Health Status Among Older Adults: Disease, 
Disability, Functional Limitation, and Perceived Health. J. Health Soc. Behav.  1993,  34,  
105-121. 
4.  Malmberg, J.; Miilunpalo, S.; Pasanen, M.; Vuori, I.; Oja, P. Characteristics of Leisure Time 
Physical Activity Associated with Risk of Decline in Perceived Health—a 10-year Follow-up of 
Middle-Aged and Elderly Men and Women. Prev. Med. 2005, 41, 141-150. 
5.  Malmberg, J.J.; Miilunpalo, S.I.; Vuori, I.M.; Pasanen, M.E.; Oja, P.; Haapanen-Niemi, N.A. A 
Health-Related Fitness and Functional Performance Test Battery for Middle-Aged and Older 
Adults: Feasibility and Health-Related Content Validity. Arch. Phys. Med. Rehabil. 2002, 83, 
666-677. 
6.  Katzmarzyk, P.T.; Janssen, I. The Economic Costs Associated with Physical Inactivity and 
Obesity in Canada: an Update. Can. J. Appl. Physiol. 2004, 29, 90-115. 
7.  Chodzko-Zajko, W.J.; Proctor, D.N.; Fiatarone Singh, M.A.; Minson, C.T.; Nigg, C.R.; Salem, G.J.; 
Skinner, J.S. American College of Sports Medicine Position Stand. Exercise and Physical Activity 
for Older Adults. Med. Sci. Sport. Exerc. 2009, 41, 1510-1530. 
8.  Stuart, M.; Chard, S.; Benvenuti, F.; Steinwachs, S. Community Exercise: A Vital Component to 
Healthy Aging. Healthc. Pap. 2009, 10, 23-28. 
9.  Physical Activity Fundamental to Preventing Disease. In Services; Department of Health & 
Human Services: Washington, D.C., USA, 2002. Sensors 2010, 10                                       
 
 
9048
10.  Ferrucci, L.; Baldasseroni, S.; Bandinelli, S.; de Alfieri, W.; Cartei, A.; Calvani, D.; Baldini, A.; 
Masotti, G.; Marchionni, N. Disease Severity and Health-Related Quality of Life Across Different 
Chronic Conditions. J. Am. Geriatr. Soc. 2000, 48, 1490-1495. 
11. de Bruin, E.D.; Hartmann, A.; Uebelhart, D.; Murer, K.; Zijlstra, W. Wearable Systems for 
Monitoring Mobility-Related Activities in Older People: A Systematic Review. Clin. Rehabil. 
2008, 22, 878-895. 
12.  Myers, A.M.; Holliday, P.J.; Harvey, K.A.; Hutchinson, K.S. Functional Performance Measures: 
Are They Superior to Self-Assessments? J. Gerontol. 1993, 48, M196-206. 
13.  Magaziner, J.; Zimmerman, S.I.; Gruber-Baldini, A.L.; Hebel, J.R.; Fox, K.M. Proxy Reporting in 
Five Areas of Functional Status. Comparison with Self-Reports and Observations of Performance. 
Am. J. Epidemiol. 1997, 146, 418-428. 
14.  Ferrucci, L.; Guralnik, J.M.; Studenski, S.; Fried, L.P.; Cutler, G.B., Jr.; Walston, J.D. Designing 
Randomized, Controlled Trials Aimed at Preventing or Delaying Functional Decline and 
Disability in Frail, Older Persons: a Consensus Report. J. Am. Geriatr. Soc. 2004, 52, 625-634. 
15. Zijlstra, W.; Aminian, K. Mobility Assessment in Older People: New Possibilities and 
Challenges. Eur. J. Ageing. 2007, 4, 3-12. 
16.  Dahl, T.H. International Classification of Functioning, Disability and Health: An Introduction and 
Discussion of its Potential Impact on Rehabilitation Services and Research. J. Rehabil. Med. 
2002, 34, 201-204. 
17.  International Classification of Functioning, Disability and Health (ICF). WHO. World Health 
Organization: Geneva, Switzerland, 2001. 
18.  Preventing Chronic Diseases: A Vital Investment. WHO Global Report; NLM Classification: WT 
500; WHO. World Health Organization: Geneva, Switzerland, 2005. 
19.  Giglia, E. PEDro: This Well-Known, Unknown. Physiotherapy Evidence Database. Eur. J. Phys. 
Rehabil. Med. 2008, 44, 477-480. 
20.  Maher, C.G.; Sherrington, C.; Herbert, R.D.; Moseley, A.M.; Elkins, M. Reliability of the PEDro 
Scale for Rating Quality of Randomized Controlled Trials. Phys. Ther. 2003, 83, 713-721. 
21. Verhagen, A.P.; de Vet, H.C.; de Bie, R.A.; Kessels, A.G.; Boers, M.; Bouter, L.M.; 
Knipschild, P.G. The Delphi List: A Criteria List for Quality Assessment of Randomized Clinical 
Trials for Conducting Systematic Reviews Developed by Delphi Consensus. J. Clin. Epidemiol. 
1998, 51, 1235-1241. 
22.  PEDro Physiotherapy Evidence Database. Available online: http://www.pedro.org.au. 
23.  Landis, J.R.; Koch, G.G. An Application of Hierarchical Kappa-Type Statistics in the Assessment 
of Majority Agreement among Multiple Observers. Biometrics 1977, 33, 363-374. 
24.  van Tulder, M.W.; Assendelft, W.J.; Koes, B.W.; Bouter, L.M. Method Guidelines for Systematic 
Reviews in the Cochrane Collaboration Back Review Group for Spinal Disorders. Spine (Phila Pa 
1976) 1997, 22, 2323-2330. 
25.  Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009, 6, 1000097. 
26.  Talbot, L.A.; Gaines, J.M.; Huynh, T.N.; Metter, E.J. A Home-Based Pedometer-Driven Walking 
Program to Increase Physical Activity in Older Adults with Osteoarthritis of the Knee: A 
Preliminary Study. J. Am. Geriatr. Soc. 2003, 51, 387-392. Sensors 2010, 10                                       
 
 
9049
27.  Toda, Y.; Toda, T.; Takemura, S.; Wada, T.; Morimoto, T.; Ogawa, R. Change in Body Fat, but 
not Body Weight or Metabolic Correlates of Obesity, is Related to Symptomatic Relief of Obese 
Patients with Knee Osteoarthritis after a Weight Control Program. J. Rheumatol.  1998,  25,  
2181-2186. 
28. Bauldoff, G.S.; Hoffman, L.A.; Zullo, T.G.; Sciurba, F.C. Exercise Maintenance Following 
Pulmonary Rehabilitation: Effect of Distractive Stimuli. Chest. 2002, 122, 948-954. 
29.  de Blok, B.M.; de Greef, M.H.; ten Hacken, N.H.; Sprenger, S.R.; Postema, K.; Wempe, J.B. The 
Effects of a Lifestyle Physical Activity Counseling Program with Feedback of a Pedometer during 
Pulmonary Rehabilitation in Patients with COPD: A Pilot Study. Patient Educ. Couns. 2006, 61, 
48-55. 
30. Sewell, L.; Singh, S.J.; Williams, J.E.; Collier, R.; Morgan, M.D. Can Individualized 
Rehabilitation Improve Functional Independence in Dlderly Patients with COPD? Chest. 2005, 
128, 1194-1200. 
31. Steele, B.G.; Belza, B.; Cain, K.C.; Coppersmith, J.; Lakshminarayan, S.; Howard, J.; 
Haselkorn, J.K. A Randomized Clinical Trial of an Activity and Exercise Adherence Intervention 
in Chronic Pulmonary Disease. Arch. Phys. Med. Rehabil. 2008, 89, 404-412. 
32.  Coghill, N.; Cooper, A.R. The Effect of a Home-Based Walking Program on Risk Factors for 
Coronary Heart Disease in Hypercholesterolaemic Men. A Randomized Controlled Trial. Prev. 
Med. 2008, 46, 545-551. 
33.  Hughes, A.R.; Mutrie, N.; Macintyre, P.D. Effect of an Exercise Consultation on Maintenance of 
Physical Activity after Completion of Phase III Exercise-Based Cardiac Rehabilitation. Eur. J. 
Cardiovasc. Prev. Rehabil. 2007, 14, 114-121. 
34. Moreau, K.L.; Degarmo, R.; Langley, J.; McMahon, C.; Howley, E.T.; Bassett, D.R., Jr.; 
Thompson, D.L. Increasing Daily Walking Lowers Blood Pressure in Postmenopausal Women. 
Med. Sci. Sport. Exerc. 2001, 33, 1825-1831. 
35.  Price, H.C.; Tucker, L.; Griffin, S.J.; Holman, R.R. The Impact of Individualised Cardiovascular 
Disease (CVD) Risk Estimates and Lifestyle Advice on Physical Activity in Individuals at High 
Risk of CVD: A Pilot 2 × 2 Factorial Understanding Risk Trial. Cardiovasc. Diabetol. 2008, 7, 
21:1-21:7. 
36.  Sohn, A.J.; Hasnain, M.; Sinacore, J.M. Impact of Exercise (walking) on Blood Pressure Levels in 
African American Adults with Newly Diagnosed Hypertension. Ethn. Dis. 2007, 17, 503-507. 
37.  Witham, M.D.; Gray, J.M.; Argo, I.S.; Johnston, D.W.; Struthers, A.D.; McMurdo, M.E. Effect of 
a Seated Exercise Program to Improve Physical Function and Health Status in Frail Patients ≥70 
Years of Age with Heart Failure. Am. J. Cardiol. 2005, 95, 1120-1124. 
38.  Araiza, P.; Hewes, H.; Gashetewa, C.; Vella, C.A.; Burge, M.R. Efficacy of a Pedometer-Based 
Physical Activity Program on Parameters of Diabetes Control in Type 2 Diabetes Mellitus. 
Metabolism 2006, 55, 1382-1387. 
39. Bjorgaas, M.; Vik, J.T.; Saeterhaug, A.; Langlo, L.; Sakshaug, T.; Mohus, R.M.; Grill, V. 
Relationship between Pedometer-Registered Activity, Aerobic Capacity and Self-Reported 
Activity and Fitness in Patients with Type 2 Diabetes. Diabetes Obes. Metab. 2005, 7, 737-744. Sensors 2010, 10                                       
 
 
9050
40.  Bjorgaas, M.R.; Vik, J.T.; Stolen, T.; Lydersen, S.; Grill, V. Regular Use of Pedometer does not 
Enhance Beneficial Outcomes in a Physical Activity Intervention Study in Type 2 Diabetes 
Mellitus. Metabolism 2008, 57, 605-611. 
41.  Engel, L.; Lindner, H. Impact of Using a Pedometer on Time Spent Walking in Older Adults with 
Type 2 Diabetes. Diabetes Educ. 2006, 32, 98-107. 
42. Keyserling, T.C.; Samuel-Hodge, C.D.; Ammerman, A.S.; Ainsworth, B.E.; Elasy, T.A.; 
Henriquez-Roldan, C.F.; Skelly, A.H.; Johnston, L.F.; Bangdiwala, S.I. A Randomized Trial of 
an Intervention to Improve Self-Care Behaviors of African-American Women with Type 2 
Diabetes: Impact on Physical Activity. Diabetes Care. 2002, 25, 1576-1583. 
43. Kirk, A.; Barnett, J.; Leese, G.; Mutrie, N. A Randomized Trial Investigating the 12-month 
Changes in Physical Activity and Health Outcomes Following a Physical Activity Consultation 
Delivered by a Person or in Written Form in Type 2 Diabetes: Time2Act. Diabetic Med. 2009, 26, 
293-301. 
44.  Kirk, A.; Mutrie, N.; MacIntyre, P.; Fisher, M. Increasing Physical Activity in People with Type 2 
Diabetes. Diabetes Care. 2003, 26, 1186-1192. 
45. Kirk, A.; Mutrie, N.; MacIntyre, P.; Fisher, M. Effects of a 12-month Physical Activity 
Counselling Intervention on Glycaemic Control and on the Status of Cardiovascular Risk Factors 
in People with Type 2 Diabetes. Diabetologia 2004, 47, 821-832. 
46.  Kirk, A.F.; Higgins, L.A.; Hughes, A.R.; Fisher, B.M.; Mutrie, N.; Hillis, S.; MacIntyre, P.D. A 
Randomized, Controlled Trial to Study the Effect of Exercise Consultation on the Promotion of 
Physical Activity in People with Type 2 Diabetes: A Pilot Study. Diabetic Med.  2001,  18,  
877-882. 
47. Kirk, A.F.; Mutrie, N.; Macintyre, P.D.; Fisher, M.B. Promoting and Maintaining Physical 
Activity in People with Type 2 Diabetes. Am. J. Prev. Med. 2004, 27, 289-296. 
48.  Lemaster, J.W.; Mueller, M.J.; Reiber, G.E.; Mehr, D.R.; Madsen, R.W.; Conn, V.S. Effect of 
Weight-Bearing Activity on Foot Ulcer Incidence in People with Diabetic Peripheral Neuropathy: 
Feet First Randomized Controlled Trial. Phys. Ther. 2008, 88, 1385-1398. 
49. Tudor-Locke, C.; Bell, R.C.; Myers, A.M.; Harris, S.B.; Ecclestone, N.A.; Rodger, N.W.; 
Lauzon, N. Controlled Outcome Evaluation of the First Step Program: A Daily Physical Activity 
Intervention for Individuals with Type II Diabetes. Int. J. Obes. Relat. Metab. Disord. 2004, 28, 
113-119. 
50.  Yates, T.; Davies, M.; Gorely, T.; Bull, F.; Khunti, K. Rationale, Design and Baseline Data from 
the Pre-Diabetes Risk Education and Physical Activity Recommendation and Encouragement 
(PREPARE) Programme Study: A Randomized Controlled Trial. Patient Educ. Couns. 2008, 73, 
264-271. 
51.  Bravata, D.M.; Smith-Spangler, C.; Sundaram, V.; Gienger, A.L.; Lin, N.; Lewis, R.; Stave, C.D.; 
Olkin, I.; Sirard, J.R. Using Pedometers to Increase Physical Activity and Improve Health: A 
Systematic Review. JAMA 2007, 298, 2296-2304. 
52. Knols, R.H.; de Bruin, E.D.; Shirato, K.; Uebelhart, D.; Aaronson, N.K. Physical Activity 
Interventions to Improve Daily Walking Activity in Cancer Survivors. BMC Cancer 2010, 10, 
406:1-406:10. Sensors 2010, 10                                       
 
 
9051
53. Crouter, S.E.; Schneider, P.L.; Karabulut, M.; Bassett, D.R., Jr. Validity of 10 Electronic 
Pedometers for Measuring Steps, Distance, and Energy Cost. Med. Sci. Sport. Exerc. 2003, 35, 
1455-1460. 
54.  Schneider, P.L.; Crouter, S.E.; Lukajic, O.; Bassett, D.R., Jr. Accuracy and Reliability of 10 
Pedometers for Measuring Steps over a 400-m Walk. Med. Sci. Sport. Exerc. 2003, 35, 1779-1784. 
55.  Crouter, S.E.; Schneider, P.L.; Bassett, D.R., Jr. Spring-Levered versus Piezo-Electric Pedometer 
Accuracy in Overweight and Obese Adults. Med. Sci. Sport. Exerc. 2005, 37, 1673-1679. 
56. Tudor-Locke, C.E.; Bell, R.C.; Myers, A.M.; Harris, S.B.; Lauzon, N.; Rodger, N.W. 
Pedometer-Determined Ambulatory Activity in Individuals with Type 2 Diabetes. Diabetes Res. 
Clin. Pract. 2002, 55, 191-199. 
57.  Corder, K.; Brage, S.; Ekelund, U. Accelerometers and Pedometers: Methodology and Clinical 
Application. Curr. Opin. Clin. Nutr. Metab. Care. 2007, 10, 597-603. 
58. Cyarto, E.V.; Myers, A.M.; Tudor-Locke, C. Pedometer Accuracy in Nursing Home and 
Community-Dwelling Older Adults. Med. Sci. Sport. Exerc. 2004, 36, 205-209. 
59.  Pearson, O.R.; Busse, M.E.; van Deursen, R.W.; Wiles, C.M. Quantification of Walking Mobility 
in Neurological Disorders. QJM 2004, 97, 463-475. 
60. Chen, K.Y.; Bassett, D.R., Jr. The Technology of Accelerometry-Based Aactivity Monitors: 
Current and Future. Med. Sci. Sport. Exerc. 2005, 37, S490-500. 
61.  Busse, M.E.; Pearson, O.R.; van Deursen, R.; Wiles, C.M. Quantified Measurement of Activity 
Provides Insight into Motor Function and Recovery in Neurological Disease. J. Neurol. 
Neurosurg. Psychiat. 2004, 75, 884-888. 
62. Coleman, K.L.; Smith, D.G.; Boone, D.A.; Joseph, A.W.; del Aguila, M.A. Step Activity 
Monitor: Long-Term, Continuous Recording of Ambulatory Function. J. Rehabil. Res. Dev. 1999, 
36, 8-18. 
63.  Duncan, P.W.; Sullivan, K.J.; Behrman, A.L.; Azen, S.P.; Wu, S.S.; Nadeau, S.E.; Dobkin, B.H.; 
Rose, D.K.; Tilson, J.K. Protocol for the Locomotor Experience Applied Post-stroke (LEAPS) 
Trial: A Randomized Controlled Trial. BMC Neurol. 2007, 7, 39:1-39:23. 
64.  Shepherd, E.F.; Toloza, E.; McClung, C.D.; Schmalzried, T.P. Step Activity Monitor: Increased 
Accuracy in Quantifying Ambulatory Activity. J. Orthop. Res. 1999, 17, 703-708. 
65.  de Bruin, E.D.; Najafi, B.; Murer, K.; Uebelhart, D.; Aminian, K. Quantification of Everyday 
Motor Function in a Geriatric Population. J. Rehabil. Res. Dev. 2007, 44, 417-428. 
66.  Grant, P.M.; Ryan, C.G.; Tigbe, W.W.; Granat, M.H. The Validation of a Novel Activity Monitor 
in the Measurement of Posture and Motion during Everyday Activities. Br. J. Sport. Med. 2006, 
40, 992-997. 
67.  Ryan, C.G.; Grant, P.M.; Tigbe, W.W.; Granat, M.H. The Validity and Reliability of a Novel 
Activity Monitor as a Measure of Walking. Br. J Sport. Med. 2006, 40, 779-784. 
68.  Brage, S.; Brage, N.; Ekelund, U.; Luan, J.; Franks, P.W.; Froberg, K.; Wareham, N.J. Effect of 
Combined Movement and Heart Rate Monitor Placement on Physical Activity Estimates during 
Treadmill Locomotion and Free-Living. Eur. J. Appl. Physiol. 2006, 96, 517-524. 
69.  Brage, S.; Brage, N.; Franks, P.W.; Ekelund, U.; Wareham, N.J. Reliability and Validity of the 
Combined Heart Rate and Movement Sensor Actiheart. Eur. J. Clin. Nutr. 2005, 59, 561-570. Sensors 2010, 10                                       
 
 
9052
70.  Crouter, S.E.; Churilla, J.R.; Bassett, D.R., Jr. Accuracy of the Actiheart for the Assessment of 
Energy Expenditure in Adults. Eur. J. Clin. Nutr. 2008, 62, 704-711. 
71.  Zhang, W.; Moskowitz, R.W.; Nuki, G.; Abramson, S.; Altman, R.D.; Bierma-Zeinstra, S.; 
Arden, N.; Brandt, K.D.; Croft, P.; Doherty, M.; Dougados, M.; Hochberg, M.; Hunter, D.J.; 
Kwoh, K.; Lohmander, L.S.; Tugwell, P. OARSI Recommendations for the Management of Hip 
and Knee Osteoarthritis, Part I: Critical Appraisal of Existing Treatment Guidelines and 
Systematic Review of Current Research Evidence. Osteoarthritis Cartilage 2007, 15, 981-1000. 
72.  Bosomworth, N.J. Exercise and Knee Osteoarthritis: Benefit or Hazard? Can. Fam. Physician. 
2009, 55, 871-878. 
73. Culhane, K.M.; O'Connor, M.; Lyons, D.; Lyons, G.M. Accelerometers in Rehabilitation 
Medicine for Older Adults. Age Ageing 2005, 34, 556-560. 
74.  Mathie, M.J.; Coster, A.C.; Lovell, N.H.; Celler, B.G. Accelerometry: Providing an Integrated, 
Practical Method for Long-Term, Ambulatory Monitoring of Human Movement. Physiol. Meas. 
2004, 25, R1-20. 
75.  Steele, B.G.; Belza, B.; Cain, K.; Warms, C.; Coppersmith, J.; Howard, J. Bodies in Motion: 
Monitoring Daily Activity and Exercise with Motion Sensors in People with Chronic Pulmonary 
Disease. J. Rehabil. Res. Dev. 2003, 40, 45-58. 
76.  Berlin, J.E.; Storti, K.L.; Brach, J.S. Using Activity Monitors to Measure Physical Activity in 
Free-Living Conditions. Phys. Ther. 2006, 86, 1137-1145. 
77.  Tudor-Locke, C.E.; Myers, A.M. Challenges and Opportunities for Measuring Physical Activity 
in Sedentary Adults. Sports Med. 2001, 31, 91-100. 
78.  Warms, C. Physical Activity Measurement in Persons with Chronic and Disabling Conditions: 
Methods, Strategies, and Issues. Fam. Community Health 2006, 29, 78S-88S. 
79.  Tudor-Locke, C.; Williams, J.E.; Reis, J.P.; Pluto, D. Utility of Pedometers for Assessing Physical 
Activity: Convergent Validity. Sports Med. 2002, 32, 795-808. 
80.  Pitta, F.; Troosters, T.; Probst, V.S.; Spruit, M.A.; Decramer, M.; Gosselink, R. Quantifying 
Physical Activity in Daily Life with Questionnaires and Motion Sensors in COPD. Eur. Respir. J. 
2006, 27, 1040-1055. 
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 